Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 2, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 770,000 Ordinary shares of 25 pence each.
- Purchase Price Range: Highest price of 1,166.5 pence per share; lowest price of 1,161 pence per share.
- Treasury Shares Held: 484,969,284 shares (8.55% of total issued share capital).
- Treasury Shares (Including Unsettled): 485,739,284 shares (9.37% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,185,949,633 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 770,000 shares on March 2, 2011. Consequently, the percentage of total voting rights held in Treasury increased to 9.37% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,185,949,633) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.37% including unsettled shares).
- Review the remaining authority for share repurchases under the mandate granted on May 6, 2010.